Search

Search Constraints

You searched for: Author/Creator Weinschenk, Toni

Search Results

1. 293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101). (9th November 2020)

2. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. (1st February 2018)

3. Front Cover: Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection. Issue 12 (27th June 2018)

4. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Issue 11 (November 2016)

5. Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Issue 1 (13th October 2017)

6. Immunopeptidomics and Peptide Expression Profiles to Develop T-Cell Receptors Against Glioma-Associated Antigens. (1st September 2019)

7. Immunopeptidomics and Peptide Expression Profiles to Develop T‐Cell Receptors Against Glioma‐Associated Antigens. (September 2019)

9. Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection. Issue 12 (10th April 2018)